{
  "nctId": "NCT02593097",
  "briefTitle": "Metformin for the Prevention of Episodic Migraine (MPEM)",
  "officialTitle": "Metformin for the Prevention of Episodic Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Study",
  "protocolDocument": {
    "nctId": "NCT02593097",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2017-01-12",
    "uploadDate": "2020-05-14T10:55",
    "size": 540411,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02593097/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "CROSSOVER",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 34,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-02",
    "completionDate": "2019-06",
    "primaryCompletionDate": "2019-06",
    "firstSubmitDate": "2015-10-28",
    "firstPostDate": "2015-10-30"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n1. age 18-65 years\n2. a diagnosis of migraine with or without aura for \\>1 year according to the International Classification of Headache Disorders-IIIb\n\nExclusion Criteria:\n\n1. a diagnosis of diabetes mellitus or polycystic ovarian syndrome\n2. overuse of acute migraine treatments\n3. failure to respond to 3 or more classes of preventive drug treatments\n4. change in dose of migraine-preventive medication within 2 months of beginning the baseline diary phase\n5. significant somatic or psychiatric disease\n6. known alcohol or other substance abuse\n7. pregnant or breastfeeding.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Headache Days",
        "description": "Total number of moderate and severe headache days",
        "timeFrame": "Baseline through end of study for a total of approximately 32 weeks"
      }
    ],
    "secondary": [
      {
        "measure": "Greater Than >50% Reduction in Migraine Days on Metformin",
        "description": "Percentage of patients whose migraines reduced by at least 50% on Metformin.",
        "timeFrame": "12 weeks"
      },
      {
        "measure": "Adverse Events",
        "description": "Total number of subjects with treatment-related adverse events",
        "timeFrame": "Baseline through end of study for a total of approximately 32 weeks"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 2,
      "otherCount": 0,
      "totalCount": 3
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "CROSSOVER"
    },
    "overallComplexityScore": 49,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:53.524Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}